{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T06:03:39Z","timestamp":1794204219614,"version":"4.8.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.esmoop.2024.103722","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T16:28:26Z","timestamp":1728059306000},"page":"103722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Systemic treatments in recurrent or metastatic salivary gland cancer: a\u00a0systematic review"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-8611","authenticated-orcid":false,"given":"D.","family":"Prost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Iseas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gatineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-6859","authenticated-orcid":false,"given":"S.","family":"Cavalieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-2708","authenticated-orcid":false,"given":"\u00c9.","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2024.103722_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12105-017-0795-0","article-title":"Update from the 4th Edition of the World Health Organization Classification of head and neck tumours: tumors of the salivary gland","volume":"11","author":"Seethala","year":"2017","journal-title":"Head Neck Pathol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103722_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/014556130608500201","article-title":"World Health Organization classification of tumours: pathology and genetics of head and neck tumours","volume":"85","author":"Thompson","year":"2006","journal-title":"Ear Nose Throat J"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103722_bib3","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1055-9965.EPI-09-0638","article-title":"Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States","volume":"18","author":"Boukheris","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103722_bib4","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s12105-022-01459-0","article-title":"Distribution and frequency of salivary gland tumours: an international multicenter study","volume":"16","author":"Alsanie","year":"2022","journal-title":"Head Neck Pathol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103722_bib5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/00016480510003174","article-title":"Salivary gland cancer in Finland 1991\u201396: an evaluation of 237 cases","volume":"125","author":"Luukkaa","year":"2005","journal-title":"Acta Otolaryngol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103722_bib6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review","volume":"12","author":"Laurie","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103722_bib7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.31353","article-title":"A\u00a0clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands","volume":"143","author":"Boon","year":"2018","journal-title":"Int J Cancer"},{"issue":"35","key":"10.1016\/j.esmoop.2024.103722_bib8","doi-asserted-by":"crossref","first-page":"59023","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification","volume":"8","author":"Takase","year":"2017","journal-title":"Oncotargetics"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103722_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamaoncol.2016.1790","article-title":"The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform","volume":"3","author":"Morris","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103722_bib10","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/annonc\/mdx399","article-title":"Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies","volume":"28","author":"Ross","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103722_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693394","article-title":"HER2 positivity in histological subtypes of salivary gland carcinoma: a systematic review and meta-analysis","volume":"11","author":"Egebjerg","year":"2021","journal-title":"Front Oncol"},{"issue":"1-2","key":"10.1016\/j.esmoop.2024.103722_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.canrad.2021.08.012","article-title":"Radiotherapy of salivary gland tumours","volume":"26","author":"Larnaudie","year":"2022","journal-title":"Cancer Radiother"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103722_bib13","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/COC.0000000000000386","article-title":"Concurrent chemoradiotherapy in the adjuvant treatment of high-risk primary salivary gland malignancies","volume":"41","author":"Gebhardt","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103722_bib14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.clon.2018.08.018","article-title":"Guidelines for clinical target volume definition for perineural spread of major salivary gland cancers","volume":"30","author":"Armstrong","year":"2018","journal-title":"Clin Oncol"},{"issue":"18","key":"10.1016\/j.esmoop.2024.103722_bib15","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1002\/cncr.27408","article-title":"Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973-2007 surveillance, epidemiology, and end results data","volume":"118","author":"Ellington","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103722_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) clinical practice guideline for diagnosis, treatment and follow-up","volume":"7","author":"Van Herpen","year":"2022","journal-title":"ESMO Open"},{"issue":"17","key":"10.1016\/j.esmoop.2024.103722_bib17","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of salivary gland malignancy: ASCO guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103722_bib18","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S","article-title":"Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients","volume":"68","author":"Licitra","year":"1991","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103722_bib19","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","article-title":"Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin","volume":"60","author":"Dreyfuss","year":"1987","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103722_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y","article-title":"Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies","volume":"91","author":"Airoldi","year":"2001","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103722_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0964-1955(97)00026-2","article-title":"Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma","volume":"33","author":"Hill","year":"1997","journal-title":"Oral Oncol"},{"key":"10.1016\/j.esmoop.2024.103722_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2016.09.022","article-title":"A\u00a0phase II study of sorafenib in recurrent and\/or metastatic salivary gland carcinomas: translational analyses and clinical impact","volume":"69","author":"Locati","year":"2016","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103722_bib23","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/cncr.30537","article-title":"Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: a multicenter phase 2 study (Korean Cancer Study Group HN14-01): Nintedanib for salivary gland cancer","volume":"123","author":"Kim","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103722_bib24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/hed.23577","article-title":"Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck: phase II trial of sorafenib in advanced adenoid cystic carcinoma","volume":"37","author":"Thomson","year":"2015","journal-title":"Head Neck"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103722_bib25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/hed.10034","article-title":"Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report","volume":"24","author":"Ruzich","year":"2002","journal-title":"Head Neck"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103722_bib26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1200\/JCO.1987.5.6.951","article-title":"Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group","volume":"5","author":"Venook","year":"1987","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103722_bib27","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hed.23647","article-title":"Phase II study of gefitinib in patients with advanced salivary gland cancers","volume":"37","author":"Jakob","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.esmoop.2024.103722_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1185198","article-title":"Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin","volume":"13","author":"Onaga","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2024.103722_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102069","article-title":"Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: a systematic review","volume":"89","author":"Uijen","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103722_bib30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.amjoto.2014.07.007","article-title":"Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy","volume":"35","author":"Yamamoto","year":"2014","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103722_bib31","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1002\/hed.23383","article-title":"Definitive treatment of androgen\u00a0receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy","volume":"36","author":"Soper","year":"2014","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103722_bib32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/2193-1801-3-363","article-title":"Hormone dependent metastatic salivary gland carcinoma: a case report","volume":"3","author":"Agbarya","year":"2014","journal-title":"Springerplus"},{"issue":"16","key":"10.1016\/j.esmoop.2024.103722_bib33","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1200\/JCO.2010.32.8351","article-title":"Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options","volume":"29","author":"Jaspers","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103722_bib34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103722_bib35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1017\/S0022215108002314","article-title":"Biological therapy of salivary duct carcinoma","volume":"123","author":"Nashed","year":"2009","journal-title":"J\u00a0Laryngol Otol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103722_bib36","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.oooo.2016.03.020","article-title":"Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab","volume":"122","author":"Ghazali","year":"2016","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103722_bib37","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/hed.20714","article-title":"Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy","volume":"30","author":"Prat","year":"2008","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103722_bib38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12032-011-9884-1","article-title":"Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review","volume":"29","author":"Kaidar-Person","year":"2012","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103722_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/2231-0770.102282","article-title":"Trastuzumab for Her2\/neu-positive metastatic salivary gland carcinoma: case report and review of the literature","volume":"2","author":"Firwana","year":"2012","journal-title":"Avicenna J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103722_bib40","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1002\/hed.23429","article-title":"Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial\u00a0growth factor combination treatment","volume":"36","author":"Falchook","year":"2014","journal-title":"Head Neck"},{"key":"10.1016\/j.esmoop.2024.103722_bib41","article-title":"Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Case Rep Oncol Med"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103722_bib42","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000445827","article-title":"Human epidermal growth factor receptor 2 (HER-2\/neu)-directed therapy for rare metastatic epithelial tumors with HER-2 amplification","volume":"9","author":"Shin","year":"2016","journal-title":"Case Rep Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103722_bib43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/17843286.2016.1173940","article-title":"Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients","volume":"71","author":"De Block","year":"2016","journal-title":"Acta Clin Belg"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103722_bib44","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/hed.24634","article-title":"Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature","volume":"39","author":"Thorpe","year":"2017","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103722_bib45","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103722_bib46","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/ijc.32795","article-title":"Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients","volume":"146","author":"Van Boxtel","year":"2020","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103722_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000381","article-title":"Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours","volume":"3","author":"Fiedler","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.103722_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105703","article-title":"Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma","volume":"125","author":"Uijen","year":"2022","journal-title":"Oral Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103722_bib49","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","article-title":"Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma","volume":"7","author":"Licitra","year":"1996","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103722_bib50","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clon.2003.12.001","article-title":"Adenocarcinoma of the salivary gland? A chemo-sensitive disease","volume":"16","author":"White","year":"2004","journal-title":"Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103722_bib51","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103722_bib52","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hed.2880140403","article-title":"Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck","volume":"14","author":"de Haan","year":"1992","journal-title":"Head Neck"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103722_bib53","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdr522","article-title":"A\u00a0phase II study of sunitinib in recurrent and\/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC","volume":"23","author":"Chau","year":"2012","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2024.103722_bib54","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.20.02903","article-title":"Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations","volume":"39","author":"Ho","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103722_bib55","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.bjoms.2010.09.013","article-title":"Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma","volume":"49","author":"Ghosal","year":"2011","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103722_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omz102","article-title":"Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report","volume":"2019","author":"Bergamini","year":"2019","journal-title":"Oxf Med Case Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103722_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73965-6","article-title":"Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma","volume":"10","author":"Niwa","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2024.103722_bib58","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.2147\/OTT.S304900","article-title":"Androgen deprivation therapy for patients with androgen-receptor-positive metastatic salivary duct carcinoma: a case report and review of the literature","volume":"14","author":"You","year":"2021","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103722_bib59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"36","key":"10.1016\/j.esmoop.2024.103722_bib60","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1200\/JCO.21.00468","article-title":"Abiraterone acetate in patients with castration-resistant, androgen receptor-expressing salivary gland cancer: a phase II trial","volume":"39","author":"Locati","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"36","key":"10.1016\/j.esmoop.2024.103722_bib61","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1200\/JCO.22.00229","article-title":"Phase II study of enzalutamide for patients with androgen receptor-positive salivary gland cancers (Alliance A091404)","volume":"40","author":"Ho","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103722_bib62","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1272\/jnms.JNMS.2023_90-504","article-title":"A\u00a0case of metastatic submandibular salivary duct carcinoma that completely responded to pembrolizumab monotherapy","volume":"90","author":"Nakaishi","year":"2023","journal-title":"J\u00a0Nippon Med Sch"},{"key":"10.1016\/j.esmoop.2024.103722_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00186","article-title":"High-grade salivary gland ductal carcinoma with unusual EGFR amplification responsive to afatinib","volume":"3","author":"Lai","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2024.103722_bib64","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.oraloncology.2017.06.023","article-title":"Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma","volume":"72","author":"van Boxtel","year":"2017","journal-title":"Oral Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103722_bib65","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/hed.25891","article-title":"Phase II trial with axitinib in recurrent and\/or metastatic salivary gland cancers of the upper aerodigestive tract","volume":"41","author":"Locati","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.esmoop.2024.103722_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1107134","article-title":"Targeted treatment in a case series of AR+, HRAS\/PIK3CA co-mutated salivary duct carcinoma","volume":"13","author":"Rieke","year":"2023","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103722_bib67","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1038\/s41591-023-02518-x","article-title":"Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial","volume":"29","author":"Vos","year":"2023","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.esmoop.2024.103722_bib68","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.3390\/cancers13174336","article-title":"Centralised RECIST assessment and clinical outcomes with lenvatinib monotherapy in recurrent and metastatic adenoid cystic carcinoma","volume":"13","author":"Feeney","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2024.103722_bib69","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103722_bib70","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/jnci\/djy088","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration","volume":"110","author":"Sauerbrei","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2024.103722_bib71","author":"Wickham"},{"key":"10.1016\/j.esmoop.2024.103722_bib72","author":"Lajeunesse"},{"key":"10.1016\/j.esmoop.2024.103722_bib73","series-title":"AFIP Atlases of Tumor and Non-Tumor Pathology, 5th Series","first-page":"719","article-title":"Tumors of the salivary glands","author":"Bishop","year":"2021"},{"key":"10.1016\/j.esmoop.2024.103722_bib74","article-title":"HER2 status in recurrent\/metastatic androgen receptor overexpressing salivary gland carcinoma patients","volume":"12","author":"Cavalieri","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103722_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103722_bib76","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221119538","article-title":"Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma","volume":"14","author":"Kawakita","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2024.103722_bib77","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2020.05.013","article-title":"Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands","volume":"136","author":"Cavalieri","year":"2020","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103722_bib78","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s11864-022-01001-y","article-title":"Metastatic adenoid cystic carcinoma: genomic landscape and emerging treatments","volume":"23","author":"de Sousa","year":"2022","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103722_bib79","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/17843286.2019.1633490","article-title":"Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients","volume":"75","author":"Couvreur","year":"2020","journal-title":"Acta Clin Belg"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103722_bib80","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdw287","article-title":"A\u00a0phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma","volume":"27","author":"Ho","year":"2016","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2024.103722_bib81","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1158\/1078-0432.CCR-23-1030","article-title":"A\u00a0phase II trial of rivoceranib, an oral cascular endothelial growth factor receptor 2 inhibitor, for recurrent or metastatic adenoid cystic carcinoma","volume":"29","author":"Hanna","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.esmoop.2024.103722_bib82","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"47","key":"10.1016\/j.esmoop.2024.103722_bib83","doi-asserted-by":"crossref","first-page":"81725","DOI":"10.18632\/oncotarget.20879","article-title":"Taking it up a NOTCH: a novel subgroup of ACC is identified","volume":"8","author":"Ferrarotto","year":"2017","journal-title":"Oncotargetics"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103722_bib84","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","article-title":"Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors","volume":"35","author":"Ferrarotto","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103722_bib85","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/1078-0432.CCR-20-1192","article-title":"Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103722_bib86","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41419-022-05133-9","article-title":"AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling","volume":"13","author":"Ferrarotto","year":"2022","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103722_bib87","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/1078-0432.CCR-15-2867-T","article-title":"Novel MYBL1 gene rearrangements with recurrent MYBL1-NFIB fusions in salivary adenoid cystic carcinomas lacking t(6;9) translocations","volume":"22","author":"Mitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.esmoop.2024.103722_bib88","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1158\/1078-0432.CCR-10-0463","article-title":"Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance","volume":"16","author":"Mitani","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103722_bib89","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/2326-6066.CIR-16-0031","article-title":"Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes","volume":"4","author":"Sridharan","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.esmoop.2024.103722_bib90","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.oraloncology.2018.11.028","article-title":"Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands","volume":"88","author":"Mosconi","year":"2019","journal-title":"Oral Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103722_bib91","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/his.13944","article-title":"The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma","volume":"75","author":"Xu","year":"2019","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103722_bib92","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T19:12:08Z","timestamp":1729797128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2059702924014923"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103722","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic treatments in recurrent or metastatic salivary gland cancer: a\u00a0systematic review","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103722"}}